IL-13 Targeting Biologics for the Treatment of Atopic Dermatitis

home / peer-exchange / il-13-targeting-biologics-for-the-treatment-of-atopic-dermatitis

Panelists discuss how IL-13 targeting biologics, including dupilumab, tralokinumab, and lebrikizumab, are advancing the treatment of atopic dermatitis, improving efficacy, safety, and patient outcomes, while addressing key challenges in diagnosis and treatment selection.

© 2024 MJH Life Sciences

All rights reserved.